A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 12, Pages 2043
Publisher
MDPI AG
Online
2019-12-20
DOI
10.3390/cancers11122043
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia
- (2019) Sebastian Kollmann et al. LEUKEMIA
- Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations—Possible Therapeutic Efficacy of Cabozantinib
- (2019) Ya-Chen Ko et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pharmacologic inhibition of STAT5 in acute myeloid leukemia
- (2018) Bettina Wingelhofer et al. LEUKEMIA
- Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia
- (2018) Kazuhiro Katayama et al. Oncotarget
- STAT5BN642H is a driver mutation for T cell neoplasia
- (2017) Ha Thi Thanh Pham et al. JOURNAL OF CLINICAL INVESTIGATION
- New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias
- (2017) Ludovic Juen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b
- (2017) Nagarajan Elumalai et al. Scientific Reports
- Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation
- (2016) Jean Claude Chomel et al. Oncotarget
- Cytokine‐induced megakaryocytic differentiation is regulated by genome‐wide loss of a uSTAT transcriptional program
- (2015) Hyun Jung Park et al. EMBO JOURNAL
- Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
- (2015) Stéphane Prost et al. NATURE
- STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
- (2015) Wolfgang Warsch et al. Oncotarget
- Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells
- (2014) L. Wu et al. CLINICAL CANCER RESEARCH
- The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse
- (2014) O. R. Bandapalli et al. HAEMATOLOGICA
- Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas
- (2014) A Nicolae et al. LEUKEMIA
- Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia
- (2014) M Kontro et al. LEUKEMIA
- BCR-ABL Affects STAT5A and STAT5B Differentially
- (2014) Michael Schaller-Schönitz et al. PLoS One
- Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein
- (2014) Abbarna A. Cumaraswamy et al. ACS Medicinal Chemistry Letters
- Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells
- (2013) H. Mistry et al. MOLECULAR CANCER THERAPEUTICS
- Flow Cytometric Quantification of All Phases of the Cell Cycle and Apoptosis in a Two-Color Fluorescence Plot
- (2013) Christine Vignon et al. PLoS One
- Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling
- (2012) Sangkil Nam et al. Molecular Oncology
- High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
- (2011) W. Warsch et al. BLOOD
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
- (2011) E. A. Nelson et al. BLOOD
- Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity
- (2011) Brent D. G. Page et al. JOURNAL OF MEDICINAL CHEMISTRY
- Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90
- (2011) Kamalika Moulick et al. Nature Chemical Biology
- Inhibitors of Stat5 protein signalling
- (2011) Abbarna A. Cumaraswamy et al. MedChemComm
- The Tumor Suppressor hTid1 Inhibits STAT5b Activity via Functional Interaction
- (2010) Isabelle Dhennin-Duthille et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations
- (2009) Cécile Parmenon et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Compound 48, a novel dual PPAR α/γ ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib
- (2009) Janina Bertz et al. LEUKEMIA RESEARCH
- 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part I: Synthesis and pharmacological evaluation
- (2008) Cécile Parmenon et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells
- (2008) C. Rathinam et al. GENES & DEVELOPMENT
- Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPARγ/STAT5 signaling pathway in macaques
- (2008) Stéphane Prost et al. JOURNAL OF CLINICAL INVESTIGATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now